Leonard Saltz
Executive Director for Clinical Value & Sustainability; Head, Colorectal Oncology Section · New York Presbyterian Hospital
Credentials: · · · · ·
History
PresentColorectal Oncology Section · New York Presbyterian Hospital
- 1986–1989
- 1983–1986
1979–1983
Research
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Nature Medicine · 2017 · 2,750 citations
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
New England Journal of Medicine · 2000 · First of 12 authors · 2,536 citations
- MW
80 papers
71 papers
- AC
70 papers · 3 as a fellow
- JS
66 papers
- DK
62 papers
- NK
61 papers
59 papers
58 papers · 14 as a resident
Grants
- 1998–2002
Molecular Prognostic Indicators in Colorectal Cancer
National Cancer Institute · R01
Contact PI · $753.6K · Sloan-Kettering Inst Can Research
Clinical trials
- 2013–2017
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Principal investigator · Completed · Phase 1
Taiho Oncology, Inc.
- 2010–2011
Principal investigator · Terminated · Phase 2
Memorial Sloan Kettering Cancer Center
- 2009–2012
Principal investigator · Completed
HiberCell, Inc.
- 2009–2013
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Principal investigator · Completed · Phase 2
Medivation, Inc.